Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADICAL: Reduced-fluence Visudyne-Lucentis Combination vs Lucentis Monotherapy in CNV secondary to AMD
NCT00492284Phase 2Completed
- Sponsor
- QLT Inc.
- Start
- Jul 2007
- Primary completion
- May 2009
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 2
01
Overview
A Phase 2 trial of verteporfin in age-related macular degeneration (AMD), sponsored by QLT Inc.. Started Jul 2007; status: completed.
02
Drugs
verteporfin
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT00492284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00492284.